IMMUCELL Reports Strong Q1 2026 Results: Revenue Jumps 28% to $10.36M, EPS Up 31% to $0.21
ICCC sits 83% above its 52-week low of $4.52.
Summary
IMMUCELL CORP reported robust first-quarter 2026 financial results, with revenue increasing 28.4% year-over-year to $10.36 million and diluted EPS rising 31.3% to $0.21. Net income attributable to stockholders also saw a substantial 34.2% increase to $1.94 million. This strong performance, driven by higher product volumes and price increases, particularly in domestic sales which grew 35.7%, indicates significant operational momentum for the company. The positive earnings report, following a recent 8-K regarding a $2 million settlement, provides a clear financial update. Traders will likely view this as a strong indicator of the company's growth trajectory, especially given the concentration of sales in Q1 due to beef calving seasonality. Investors should monitor the sustainability of domestic sales growth and the impact of operational changes like the Caddie facility repurposing.
At the time of this announcement, ICCC was trading at $8.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.7M. The 52-week trading range was $4.52 to $9.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.